In one paragraphReview in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Caroline Rodrigues Chaves Dos ReisFundação Oswaldo Cruz, Fiocruz, Instituto de Tecnologia em Fármacos, Programa de Pós-Graduação em Pesquisa Translacional em Fármacos e Medicamentos, Rio de Janeiro, RJ, Brazil.ORCID https://orcid.org/0000-0001-8982-242X Hellen Valério Chaves Moura de SouzaFundação Oswaldo Cruz, Fiocruz, Instituto de Tecnologia em Fármacos, Programa de Pós-Graduação em Pesquisa Translacional em Fármacos e Medicamentos, Rio de Janeiro, RJ, Brazil.ORCID https://orcid.org/0000-0003-0152-0545 Lidia Corrêa ParraFundação Oswaldo Cruz, Fiocruz, Instituto de Tecnologia em Fármacos, Programa de Pós-Graduação em Pesquisa Translacional em Fármacos e Medicamentos, Rio de Janeiro, RJ, Brazil.ORCID https://orcid.org/0009-0005-0134-4547 Guilber Valério Chaves Moura de SouzaFundação Oswaldo Cruz, Fiocruz, Instituto de Tecnologia em Fármacos, Laboratório de Síntese de Fármacos (LASFAR), Rio de Janeiro, RJ, Brazil.ORCID https://orcid.org/0009-0009-2689-3488 Nubia BoechatFundação Oswaldo Cruz, Fiocruz, Instituto de Tecnologia em Fármacos, Programa de Pós-Graduação em Pesquisa Translacional em Fármacos e Medicamentos, Rio de Janeiro, RJ, Brazil.ORCID https://orcid.org/0000-0003-0146-2218 Lucas Villas Bôas HoelzFundação Oswaldo Cruz, Fiocruz, Instituto de Tecnologia em Fármacos, Programa de Pós-Graduação em Pesquisa Translacional em Fármacos e Medicamentos, Rio de Janeiro, RJ, Brazil.ORCID https://orcid.org/0000-0001-5592-3089 Tácio Vinício Amorim FernandesFundação Oswaldo Cruz, Fiocruz, Instituto de Tecnologia em Fármacos, Programa de Pós-Graduação em Pesquisa Translacional em Fármacos e Medicamentos, Rio de Janeiro, RJ, Brazil.ORCID https://orcid.org/0000-0001-5881-9519 Funding
Conselho Nacional de Desenvolvimento Científico e Tecnológico 440006/2022-8Conselho Nacional de Desenvolvimento Científico e Tecnológico 447623/2024-9Coordenação de Aperfeiçoamento de Pessoal de Nível Superior Finance Code 001Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro FAPERJ-JCNE E-26/201.268/2021
6 · The paper itselfAbstract
Over three decades, cruzain, the principal cysteine protease of Trypanosoma cruzi and a validated drug target for Chagas disease, has accumulated 215 inhibitors with IC
Indexed as
Chagas DiseaseCysteine EndopeptidasesCysteine Proteinase InhibitorsProtozoan ProteinsTrypanocidal AgentsTrypanosoma cruziDrug DesignHumansMolecular Docking SimulationMolecular Dynamics SimulationQuantitative Structure-Activity Relationshipcruzain, Trypanosoma cruziCysteine EndopeptidasesCysteine Proteinase InhibitorsProtozoan ProteinsTrypanocidal AgentsChagas diseasecomputational drug designcruzaincysteine protease inhibitorsmolecular dynamicsmultiparametric optimisationQSARtranslational failureTrypanosoma cruzi
Identifiers
PMID42290031
PMCPMC13266285
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390